StockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)

Analysts at StockNews.com assumed coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) in a research note issued on Saturday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Trading Up 3.5 %

Shares of NASDAQ:ADMP opened at $0.19 on Friday. The stock has a 50 day moving average of $0.19 and a 200 day moving average of $0.26. Adamis Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $0.73.

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) last posted its earnings results on Monday, November 14th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The firm had revenue of $1.51 million during the quarter.

Hedge Funds Weigh In On Adamis Pharmaceuticals

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp lifted its position in Adamis Pharmaceuticals Co. (NASDAQ:ADMPGet Rating) by 13.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 475,373 shares of the specialty pharmaceutical company’s stock after purchasing an additional 55,168 shares during the quarter. State Street Corp owned about 0.32% of Adamis Pharmaceuticals worth $271,000 as of its most recent SEC filing. 8.57% of the stock is currently owned by hedge funds and other institutional investors.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.

Featured Articles

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.